Journal Article

Uncommon Evolution From Acute Myeloid Leukaemia to JAK2‐Mutated Myeloproliferative Neoplasm: Evidence of Clonal Persistence and Divergence From TET2/SRSF2‐Mutated Haematopoietic Progenitors

Turingan, Mark Anthony, Hezaveh, Ehsan Bahrami, Wei, Cuihong, Maze, Dawn, Chang, Hong, Cheung, Verna

2025

Overview

ABSTRACT Background The emergence of JAK2‐mutated myeloproliferative neoplasms (MPNs) after remission from acute myeloid leukaemia (AML) is exceedingly rare. Case Description This case series describes two patients who developed JAK2‐mutated MPNs years after achieving AML remission, each retaining persistent TET2 and SRSF2 mutations while losing AML‐defining mutations. Pathogenetic Insight Findings support clonal persistence from a shared haematopoietic progenitor with divergent progression into distinct myeloid neoplasms. A two‐pathway model is proposed to explain this trajectory. Implications These observations highlight the biological relevance of CHIP‐associated mutations and underscore the value of post‐remission molecular surveillance to detect emerging secondary neoplasms in AML survivors. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.

• Publisher: Wiley